TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02119832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovasccular AVF (EndoAVF)
Description: The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
Study: NCT05168878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-second BeSMART video
Description: 30 second video focused on education about child gun deaths and responsible gun storage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-minute BeSMART video
Description: 3-minute video focused on education about child gun deaths and responsible gun storage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3-minute BeSMART video
Description: 3-minute video focused on education about child gun deaths and responsible gun storage
Study: NCT01022294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrousoxide-oxygen and atmospheric air
Description: Nitrousoxide-oxygen and atmospheric air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atmospheric air; nitrousoxide-oxygen
Description: Atmospheric air; nitrousoxide-oxygen
Study: NCT02568228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean and fatty fish
Description: The fish group will be open labeled.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
Study: NCT02487771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: 600 mg DHA capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
Study: NCT01865617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV
Study: NCT02827786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Acoustic Imaging
Description: Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
Study: NCT03591757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
Study: NCT02500979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Description: Pramlintide acetate administered by a separate pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by separate pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lispro insulin U-100
Description: Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro insulin U-100
Description: Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular insulin U-100
Description: Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin U-100
Description: Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
Study: NCT02172300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation capsules
Study: NCT00799734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXD
Description: Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXD
Description: Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
Study: NCT05668364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outdoor cold air exposure
Description: Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
Study: NCT02770092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study: NCT04906369

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT00707213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
Study: NCT03412162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethnic and Racial Identity Promotion
Description: See arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Skills Promotion
Description: See arm description
Study: NCT03482817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ze 117
Description: Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe drug cocktail
Description: Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
Study: NCT01284140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and circadian rhythm promotion
Description: This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care.
Study: NCT01197989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEPSO cloth
Description: TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard cloth
Description: Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Study: NCT03514407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
Study: NCT03741244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
Study: NCT00726349

Intervention type: OTHER
Intervention: No intervention
Description: Observational study.
Study: NCT01160120

Intervention type: DRUG
Group type: OTHER
Intervention: generic FDC of TDF/3TC/EFV
Description: Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
Study: NCT03452176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler
Description: Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Scrambler Sham Control
Description: Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
Study: NCT01290536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
Description: Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
Study: NCT04896125

Intervention type: DRUG
Intervention: Lumigan PF; Xalatan
Description: Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.

Intervention type: DRUG
Intervention: Lumigan PF; Xalatan
Description: Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
Study: NCT00734214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl
Description: Intravenous Fluid~Isotonic Parenteral Fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45%NaCl
Description: Intravenous Fluid~Hypotonic Parenteral Fluid
Study: NCT00431639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal Assisted Therapy
Description: Every subject will be exposed to both treatment and comparison conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal Assisted Therapy
Description: Every subject will be exposed to both treatment and comparison conditions.
Study: NCT02669303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma group
Description: Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone group
Description: Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
Study: NCT01193582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to \< 212 days of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to \< 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to \< 24 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to \< 72 months of age
Study: NCT04478084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free VRVg-2
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free VRVg-2
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free VRVg-2
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: Pharmaceutical form:freeze-dried Route of administration: intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)
Description: Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)
Description: Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)
Description: Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)
Description: Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
Study: NCT01812538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIC075V
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIC075V
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIC075V
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DIC075V
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.
Study: NCT04516421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oat drink
Description: placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
Study: NCT02597933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00004221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01083446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Cognitive and executive functions during fast
Study: NCT02454712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 is an oxycodone prodrug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone extended-release
Description: Oxycodone extended-release is the comparator drug
Study: NCT01246232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
Study: NCT02454712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Hydrochloride
Description: Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
Study: NCT03764540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone
Description: Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel plus prednisone
Description: Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles.
Study: NCT02195310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ Incision Management System
Description: Prevena™ Incision Management System is used after sternotomy on the closed incision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sterile wound dressings
Description: Conventional sterile wound dressings are placed after sternotomy on the closed incision
Study: NCT03777813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
Description: Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
Description: Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)